Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 Overlooked Growth Stocks to Buy Now.
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the overlooked growth stocks to buy now. On April 13, Travere Therapeutics announced that the US FDA granted full approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis/FSGS. This milestone makes FILSPARI the first and only FDA-approved medication for FSGS, a rare kidney disease that causes scarring in the filtering units of the kidney. The approval specifically covers adult and pediatric patients aged 8 years and older who do not have nephrotic syndrome.
The approval is supported by data from the Phase 3 DUPLEX Study, the largest interventional trial ever conducted in FSGS. In patients without nephrotic syndrome, those treated with FILSPARI achieved a statistically significant 48% reduction in proteinuria (excess protein in the urine) after 108 weeks, compared to a 27% reduction in those taking the active comparator, irbesartan. Additionally, FILSPARI showed a benefit in preserving the estimated glomerular filtration rate/eGFR, a key measure of kidney function, while maintaining a safety profile comparable to existing standard-of-care treatments.
FILSPARI uses a dual mechanism of action, targeting both endothelin A and angiotensin II receptors. By blocking these two pathways, the drug helps reduce the inflammation and scarring that typically lead to kidney failure. This approval expands Travere Therapeutics Inc.’s (NASDAQ:TVTX) reach in the rare kidney disease market, increasing the total addressable US population for FILSPARI (which is already approved for IgA nephropathy) to more than 100,000 patients.
Travere Therapeutics Inc. (NASDAQ:TVTX) is a biopharma company that identifies, develops, and delivers life-changing therapies for people living with rare kidney and metabolic diseases. By focusing on conditions with high unmet needs, such as IgA nephropathy and cystinuria, the company sets new standards of care for patients.
While we acknowledge the risk and potential of TVTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TVTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
